{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:37:31Z","timestamp":1790127451409,"version":"4.0.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Slovenian Research Agency","doi-asserted-by":"crossref","award":["grants (no. P3-0003)"],"award-info":[{"award-number":["grants (no. P3-0003)"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"DOI":"10.1007\/s10585-025-10384-9","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:32:53Z","timestamp":1763706773000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Importance of the timing of combined electrochemotherapy and immunotherapy in the treatment of advanced melanoma"],"prefix":"10.1007","volume":"43","author":[{"given":"Erika Gabriella","family":"Kis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Brizio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Riva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Peric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Odili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Mascherini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Russano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Giorgione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Matteucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siva","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Tauceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadrian","family":"Nassabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Carpen\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Colavitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Kunte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Bertino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Seccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"de Terlizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Sersa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"issue":"30","key":"10384_CR1","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.1200\/JCO.23.01136","volume":"41","author":"R Seth","year":"2023","unstructured":"Seth R, Agarwala SS, Messersmith H et al (2023) Systemic therapy for melanoma: ASCO guideline update. JCO 41(30):4794\u20134820. https:\/\/doi.org\/10.1200\/JCO.23.01136","journal-title":"JCO"},{"key":"10384_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115152","volume":"215","author":"C Garbe","year":"2025","unstructured":"Garbe C, Amaral T, Peris K et al (2025) European consensus-based interdisciplinary guideline for melanoma. Part 1: diagnostics\u2014update 2024. Eur J Cancer 215:115152. https:\/\/doi.org\/10.1016\/j.ejca.2024.115152","journal-title":"Eur J Cancer"},{"issue":"1","key":"10384_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/intimm\/dxu095","volume":"27","author":"GK Philips","year":"2015","unstructured":"Philips GK, Atkins M (2015) Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. Int Immunol 27(1):39\u201346. https:\/\/doi.org\/10.1093\/intimm\/dxu095","journal-title":"Int Immunol"},{"issue":"6","key":"10384_CR4","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.cell.2015.08.038","volume":"162","author":"DR Littman","year":"2015","unstructured":"Littman DR (2015) Releasing the brakes on cancer immunotherapy. Cell 162(6):1186\u20131190. https:\/\/doi.org\/10.1016\/j.cell.2015.08.038","journal-title":"Cell"},{"issue":"10","key":"10384_CR5","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.7150\/jca.72210","volume":"13","author":"J Pradeep","year":"2022","unstructured":"Pradeep J, Win TT, Aye SN, Sreeramareddy CT (2022) Efficacy and safety of immune checkpoint inhibitors for advanced malignant melanoma: a meta-analysis on monotherapy vs combination therapy. J Cancer 13(10):3091\u20133102. https:\/\/doi.org\/10.7150\/jca.72210","journal-title":"J Cancer"},{"issue":"19","key":"10384_CR6","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M et al (2017) Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 377(19):1824\u20131835. https:\/\/doi.org\/10.1056\/NEJMoa1709030","journal-title":"N Engl J Med"},{"issue":"17","key":"10384_CR7","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1158\/1078-0432.CCR-22-3145","volume":"29","author":"J Larkin","year":"2023","unstructured":"Larkin J, Del Vecchio M, Mandal\u00e1 M et al (2023) Adjuvant nivolumab versus ipilimumab in resected stage III\/IV melanoma: 5-year efficacy and biomarker results from CheckMate 238. Clin Cancer Res 29(17):3352\u20133361. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3145","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10384_CR8","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/S1470-2045(21)00081-4","volume":"22","author":"A Bottomley","year":"2021","unstructured":"Bottomley A, Coens C, Mierzynska J et al (2021) Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol 22(5):655\u2013664. https:\/\/doi.org\/10.1016\/S1470-2045(21)00081-4","journal-title":"Lancet Oncol"},{"issue":"33","key":"10384_CR9","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1200\/JCO.20.02110","volume":"38","author":"AMM Eggermont","year":"2020","unstructured":"Eggermont AMM, Blank CU, Mandala M et al (2020) Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG\/KEYNOTE-054 trial. JCO 38(33):3925\u20133936. https:\/\/doi.org\/10.1200\/JCO.20.02110","journal-title":"JCO"},{"issue":"19","key":"10384_CR10","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M et al (2018) Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 378(19):1789\u20131801. https:\/\/doi.org\/10.1056\/NEJMoa1802357","journal-title":"N Engl J Med"},{"issue":"4","key":"10384_CR11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/00001813-199804000-00005","volume":"9","author":"J Gehl","year":"1998","unstructured":"Gehl J, Skovsgaard T, Mir LM (1998) Enhancement of cytotoxicity by electropermeabilization: an improved method for screening drugs. Anticancer Drugs 9(4):319\u2013326. https:\/\/doi.org\/10.1097\/00001813-199804000-00005","journal-title":"Anticancer Drugs"},{"issue":"1","key":"10384_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0169-409X(98)00066-0","volume":"35","author":"LM Mir","year":"1999","unstructured":"Mir LM, Orlowski S (1999) Mechanisms of electrochemotherapy. Adv Drug Deliv Rev 35(1):107\u2013118. https:\/\/doi.org\/10.1016\/S0169-409X(98)00066-0","journal-title":"Adv Drug Deliv Rev"},{"issue":"12","key":"10384_CR13","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1038\/bjc.1998.388","volume":"77","author":"LM Mir","year":"1998","unstructured":"Mir LM, Glass LF, Sersa G et al (1998) Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br J Cancer 77(12):2336\u20132342. https:\/\/doi.org\/10.1038\/bjc.1998.388","journal-title":"Br J Cancer"},{"issue":"4","key":"10384_CR14","doi-asserted-by":"publisher","DOI":"10.4161\/onci.28131","volume":"3","author":"CY Calvet","year":"2014","unstructured":"Calvet CY, Famin D, Andr\u00e9 FM, Mir LM (2014) Electrochemotherapy with bleomycin induces hallmarks of immunogenic cell death in murine colon cancer cells. OncoImmunology 3(4):e28131. https:\/\/doi.org\/10.4161\/onci.28131","journal-title":"OncoImmunology"},{"key":"10384_CR15","doi-asserted-by":"publisher","first-page":"1336866","DOI":"10.3389\/fimmu.2023.1336866","volume":"14","author":"B Hadzialjevic","year":"2024","unstructured":"Hadzialjevic B, Omerzel M, Trotovsek B et al (2024) Electrochemotherapy combined with immunotherapy\u2014a promising potential in the treatment of cancer. Front Immunol 14:1336866. https:\/\/doi.org\/10.3389\/fimmu.2023.1336866","journal-title":"Front Immunol"},{"issue":"3","key":"10384_CR16","first-page":"391","volume":"48","author":"M Snoj","year":"2007","unstructured":"Snoj M, Cemazar M, Slekovec Kolar B, Sersa G (2007) Effective treatment of multiple unresectable skin melanoma metastases by electrochemotherapy. Croat Med J 48(3):391\u2013395","journal-title":"Croat Med J"},{"issue":"8","key":"10384_CR17","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1080\/0284186X.2017.1290274","volume":"56","author":"H Falk","year":"2017","unstructured":"Falk H, Lambaa S, Johannesen HH, Wooler G, Venzo A, Gehl J (2017) Electrochemotherapy and calcium electroporation inducing a systemic immune response with local and distant remission of tumors in a patient with malignant melanoma\u2014a case report. Acta Oncol 56(8):1126\u20131131. https:\/\/doi.org\/10.1080\/0284186X.2017.1290274","journal-title":"Acta Oncol"},{"issue":"5","key":"10384_CR18","doi-asserted-by":"publisher","first-page":"925","DOI":"10.3390\/vaccines11050925","volume":"11","author":"U Kesar","year":"2023","unstructured":"Kesar U, Markelc B, Jesenko T et al (2023) Effects of electrochemotherapy on immunologically important modifications in tumor cells. Vaccines (Basel) 11(5):925. https:\/\/doi.org\/10.3390\/vaccines11050925","journal-title":"Vaccines (Basel)"},{"issue":"10","key":"10384_CR19","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s00262-015-1724-2","volume":"64","author":"G Sersa","year":"2015","unstructured":"Sersa G, Teissie J, Cemazar M et al (2015) Electrochemotherapy of tumors as in situ vaccination boosted by immunogene electrotransfer. Cancer Immunol Immunother 64(10):1315\u20131327. https:\/\/doi.org\/10.1007\/s00262-015-1724-2","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"10384_CR20","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/S0360-3016(97)81378-8","volume":"36","author":"P Giraud","year":"1996","unstructured":"Giraud P, Bachaud JM, Teissie J, Rols MP (1996) Effects of electrochemotherapy on cutaneous metastases of human malignant melanoma. Int J Radiat Oncol Biol Phys 36(5):1285. https:\/\/doi.org\/10.1016\/S0360-3016(97)81378-8","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"10384_CR21","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1111\/bjd.15340","volume":"176","author":"C Kunte","year":"2017","unstructured":"Kunte C, Letul\u00e9 V, Gehl J, Dahlstroem K, Curatolo P, Rotunno R, Muir T, Occhini A, Bertino G, Powell B, Saxinger W, Lechner G, Liew S-H, Pritchard-Jones R, Rutkowski P, Zdzienicki M, Mowatt D, Sykes AJ, Orlando A, Mitsala G, Rossi CR, Campana L, Brizio M, de Terlizzi F, Quaglino P, Odili J (2017) Electrochemotherapy in the treatment of metastatic malignant melanoma: a prospective cohort study by InspECT. Br J Dermatol 176(6):1475\u20131485. https:\/\/doi.org\/10.1111\/bjd.15340","journal-title":"Br J Dermatol"},{"issue":"3","key":"10384_CR22","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3109\/0284186X.2014.992546","volume":"54","author":"P Quaglino","year":"2015","unstructured":"Quaglino P, Matthiessen LW, Curatolo P et al (2015) Predicting patients at risk for pain associated with electrochemotherapy. Acta Oncol 54(3):298\u2013306. https:\/\/doi.org\/10.3109\/0284186X.2014.992546","journal-title":"Acta Oncol"},{"key":"10384_CR23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ejca.2020.06.020","volume":"138","author":"AJP Clover","year":"2020","unstructured":"Clover AJP, de Terlizzi F, Bertino G et al (2020) Electrochemotherapy in the treatment of cutaneous malignancy: outcomes and subgroup analysis from the cumulative results from the pan-European International Network for Sharing Practice in Electrochemotherapy database for 2482 lesions in 987 patients (2008\u20132019). Eur J Cancer 138:30\u201340. https:\/\/doi.org\/10.1016\/j.ejca.2020.06.020","journal-title":"Eur J Cancer"},{"issue":"6","key":"10384_CR24","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/j.1524-4725.2011.01951.x","volume":"37","author":"E Kis","year":"2011","unstructured":"Kis E, Ol\u00e1h J, \u00d3csai H et al (2011) Electrochemotherapy of cutaneous metastases of melanoma\u2014a case series study and systematic review of the evidence. Dermatol Surg 37(6):816\u2013824. https:\/\/doi.org\/10.1111\/j.1524-4725.2011.01951.x","journal-title":"Dermatol Surg"},{"issue":"1","key":"10384_CR25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2024.11.006","volume":"36","author":"T Amaral","year":"2025","unstructured":"Amaral T, Ottaviano M, Arance A et al (2025) Cutaneous melanoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol 36(1):10\u201330. https:\/\/doi.org\/10.1016\/j.annonc.2024.11.006","journal-title":"Ann Oncol"},{"issue":"6","key":"10384_CR26","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1008842","volume":"4","author":"N Mozzillo","year":"2015","unstructured":"Mozzillo N, Simeone E, Benedetto L et al (2015) Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy. OncoImmunology 4(6):e1008842. https:\/\/doi.org\/10.1080\/2162402X.2015.1008842","journal-title":"OncoImmunology"},{"issue":"17","key":"10384_CR27","doi-asserted-by":"publisher","first-page":"4289","DOI":"10.3390\/cancers13174289","volume":"13","author":"LG Campana","year":"2021","unstructured":"Campana LG, Peric B, Mascherini M et al (2021) Combination of Pembrolizumab with electrochemotherapy in cutaneous metastases from melanoma: a comparative retrospective study from the InspECT and Slovenian Cancer Registry. Cancers 13(17):4289. https:\/\/doi.org\/10.3390\/cancers13174289","journal-title":"Cancers"},{"issue":"1084","key":"10384_CR28","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20170457","volume":"91","author":"B Somarouthu","year":"2018","unstructured":"Somarouthu B, Lee SI, Urban T, Sadow CA, Harris GJ, Kambadakone A (2018) Immune-related tumour response assessment criteria: a comprehensive review. BJR 91(1084):20170457. https:\/\/doi.org\/10.1259\/bjr.20170457","journal-title":"BJR"},{"issue":"11","key":"10384_CR29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejcsup.2006.08.003","volume":"4","author":"LM Mir","year":"2006","unstructured":"Mir LM, Gehl J, Sersa G et al (2006) Standard operating procedures of the electrochemotherapy: instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes. Eur J Cancer Suppl 4(11):14\u201325. https:\/\/doi.org\/10.1016\/j.ejcsup.2006.08.003","journal-title":"Eur J Cancer Suppl"},{"issue":"7","key":"10384_CR30","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1080\/0284186X.2018.1454602","volume":"57","author":"J Gehl","year":"2018","unstructured":"Gehl J, Sersa G, Matthiessen LW et al (2018) Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases. Acta Oncol 57(7):874\u2013882. https:\/\/doi.org\/10.1080\/0284186X.2018.1454602","journal-title":"Acta Oncol"},{"issue":"11","key":"10384_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejcsup.2006.08.002","volume":"4","author":"M Marty","year":"2006","unstructured":"Marty M, Sersa G, Garbay JR et al (2006) Electrochemotherapy\u2014an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. Eur J Cancer Suppl 4(11):3\u201313. https:\/\/doi.org\/10.1016\/j.ejcsup.2006.08.002","journal-title":"Eur J Cancer Suppl"},{"key":"10384_CR32","doi-asserted-by":"publisher","first-page":"1470432","DOI":"10.3389\/fimmu.2025.1470432","volume":"16","author":"K Ur\u0161i\u010d Valentinuzzi","year":"2025","unstructured":"Ur\u0161i\u010d Valentinuzzi K, Kamen\u0161ek U, Kranjc Brezar S et al (2025) Electrochemotherapy with bleomycin, oxaliplatin, or cisplatin in mouse tumor models, from tumor ablation to in situ vaccination. Front Immunol 16:1470432. https:\/\/doi.org\/10.3389\/fimmu.2025.1470432","journal-title":"Front Immunol"},{"issue":"8","key":"10384_CR33","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00262-016-1856-z","volume":"65","author":"MV Heppt","year":"2016","unstructured":"Heppt MV, Eigentler TK, K\u00e4hler KC et al (2016) Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis. Cancer Immunol Immunother 65(8):951\u2013959. https:\/\/doi.org\/10.1007\/s00262-016-1856-z","journal-title":"Cancer Immunol Immunother"},{"key":"10384_CR34","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.jconrel.2021.03.009","volume":"332","author":"K Ursic","year":"2021","unstructured":"Ursic K, Kos S, Kamensek U et al (2021) Potentiation of electrochemotherapy effectiveness by immunostimulation with IL-12 gene electrotransfer in mice is dependent on tumor immune status. J Control Release 332:623\u2013635. https:\/\/doi.org\/10.1016\/j.jconrel.2021.03.009","journal-title":"J Control Release"},{"issue":"1","key":"10384_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-019-0272-7","volume":"17","author":"O Kepp","year":"2020","unstructured":"Kepp O, Marabelle A, Zitvogel L, Kroemer G (2020) Oncolysis without viruses\u2014inducing systemic anticancer immune responses with local therapies. Nat Rev Clin Oncol 17(1):49\u201364. https:\/\/doi.org\/10.1038\/s41571-019-0272-7","journal-title":"Nat Rev Clin Oncol"},{"key":"10384_CR36","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ejca.2021.08.044","volume":"158","author":"MM De Meza","year":"2021","unstructured":"De Meza MM, Ismail RK, Rauwerdink D et al (2021) Adjuvant treatment for melanoma in clinical practice\u2014trial versus reality. Eur J Cancer 158:234\u2013245. https:\/\/doi.org\/10.1016\/j.ejca.2021.08.044","journal-title":"Eur J Cancer"},{"issue":"19","key":"10384_CR37","doi-asserted-by":"publisher","first-page":"4823","DOI":"10.3390\/cancers15194823","volume":"15","author":"A Rogiers","year":"2023","unstructured":"Rogiers A, Willemot L, McDonald L et al (2023) Real-world effectiveness, safety, and health-related quality of life in patients receiving adjuvant Nivolumab for Melanoma in Belgium and Luxembourg: results of PRESERV MEL. Cancers (Basel) 15(19):4823. https:\/\/doi.org\/10.3390\/cancers15194823","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10384_CR38","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1111\/jdv.18779","volume":"37","author":"K Schumann","year":"2023","unstructured":"Schumann K, Mauch C, Klespe K, Klespe KC, Loquai C, Nikfarjam U, Schlaak M, Ak\u00e7etin L, K\u00f6lblinger P, Hoellwerth M, Meissner M, Mengi G, Braun AD, Mengoni M, Dummer R, Mangana J, Sindrilaru MA, Radmann D, Hafner C, Freund J, Rappersberger K, Weihsengruber F, Meiss F, Reinhardt L, Meier F, Rainer B, Richtig E, Ressler JM, H\u00f6ller C, Eigentler T, Amaral T, Peitsch WK, Hillen U, Harth W, Ziller F, Schatton K, Gambichler T, Susok L, Maul LV, L\u00e4ubli H, Debus D, Weishaupt C, B\u00f6rger S, Sievers K, Haferkamp S, Zenderowski V, Nguyen VA, Wanner M, Gutzmer R, Terheyden P, K\u00e4hler K, Emmert S, Thiem A, Sachse M, Gercken-Riedel S, Kaune KM, Thoms KM, Heinzerling L, Heppt MV, Tratzmiller S, Hoetzenecker W, \u00d6llinger A, Steiner A, Peinhaupt T, Podda M, Schmid S, Wollina U, Biedermann T, Posch C (2023) Real\u2010world outcomes using PD \u20101 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland. J Eur Acad Dermatol Venereol 37(5):894\u2013906. https:\/\/doi.org\/10.1111\/jdv.18779","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10384_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114023","volume":"202","author":"RB Holmstroem","year":"2024","unstructured":"Holmstroem RB, Pedersen S, Jurlander R, Madsen K, Donia M, Ruhlmann CH, Schmidt H, Haslund CA, Bastholt L, Svane IM, Ellebaek E (2024) Outcome of adjuvant immunotherapy in a real-world nation-wide cohort of patients with melanoma. Eur J Cancer 202:114023. https:\/\/doi.org\/10.1016\/j.ejca.2024.114023","journal-title":"Eur J Cancer"},{"issue":"3","key":"10384_CR40","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1200\/JCO.22.00533","volume":"41","author":"JS Weber","year":"2023","unstructured":"Weber JS, Schadendorf D, Del Vecchio M et al (2023) Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915). J Clin Oncol 41(3):517\u2013527. https:\/\/doi.org\/10.1200\/JCO.22.00533","journal-title":"J Clin Oncol"}],"container-title":["Clinical & Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-025-10384-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-025-10384-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-025-10384-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:32:56Z","timestamp":1763706776000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-025-10384-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["10384"],"URL":"https:\/\/doi.org\/10.1007\/s10585-025-10384-9","relation":{},"ISSN":["1573-7276"],"issn-type":[{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest. Francesca de Terlizzi is an IGEA employer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol was approved by the National Medical Ethics Committee of the Republic of Slovenia (Permit No. 102\/09\/14).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethic committee"}}],"article-number":"2"}}